New: Introducing “Why Is It Moving?” - lightning-fast, AI-driven explanations of stock moves

HUTCHMED (China) Limited

Contributing Author

Recent Articles by HUTCHMED (China) Limited

11 hours	HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee HCM GlobeNewswire
Oct-13	HUTCHMED Highlights FRUSICA-2 Registration Trial Data to be Presented at the 2025 ESMO Congress HCM GlobeNewswire
Oct-01	HUTCHMED Highlights Clinical Data to be Presented at the ESMO Congress 2025 HCM GlobeNewswire
Sep-11	Save the Date: HUTCHMED to Present R&D Updates on October 31, 2025 HCM GlobeNewswire
Sep-04	HUTCHMED Highlights Clinical Data to be Presented at the 2025 World Conference of Lung Cancer and the CSCO Annual Meeting 2025 HCM GlobeNewswire
Aug-24	HUTCHMED Announces Appointment of Acting Chief Executive Officer HCM GlobeNewswire
Aug-19	HUTCHMED Completes Patient Enrollment of SANOVO Phase III Trial of ORPATHYS and TAGRISSO Combination as a First-Line Therapy for Certain Lung Cancer Patients in China HCM GlobeNewswire
Aug-07	HUTCHMED Reports 2025 Interim Results HCM GlobeNewswire
Jul-03	HUTCHMED to Announce 2025 Half-Year Financial Results HCM GlobeNewswire
Jun-30	HUTCHMED Announces China Approval for ORPATHYS in Combination with TAGRISSO for the Treatment of Lung Cancer Patients with MET Amplification After Progression on First-Line EGFR Inhibitor Therapy HCM GlobeNewswire
Jun-04	HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Renal Cell Carcinoma HCM GlobeNewswire
Jun-01	HUTCHMED Highlights SACHI Phase III Study Data Presented at the 2025 ASCO Annual Meeting HCM GlobeNewswire
May-22	HUTCHMED Highlights Clinical Data to be Presented at the 2025 ASCO Annual Meeting HCM GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 Finviz.com. All Rights Reserved.